Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) Sees Large Drop in Short Interest

Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) was the target of a significant decline in short interest during the month of January. As of January 15th, there was short interest totaling 27,133 shares, a decline of 66.6% from the December 31st total of 81,204 shares. Based on an average daily volume of 30,983 shares, the days-to-cover ratio is presently 0.9 days. Approximately 0.2% of the company’s stock are short sold. Approximately 0.2% of the company’s stock are short sold. Based on an average daily volume of 30,983 shares, the days-to-cover ratio is presently 0.9 days.

Hong Kong Pharma Digital Technology Stock Performance

HKPD traded down $0.01 during midday trading on Wednesday, reaching $0.84. The company had a trading volume of 12,030 shares, compared to its average volume of 25,729. Hong Kong Pharma Digital Technology has a 1 year low of $0.68 and a 1 year high of $2.76. The business has a 50-day moving average of $0.83 and a two-hundred day moving average of $1.12.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Hong Kong Pharma Digital Technology in a research report on Friday, January 9th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

About Hong Kong Pharma Digital Technology

Hong Kong Pharma is an exempted limited liability company formed under the laws of the Cayman Islands on August 17, 2023. As a holding company with no material operations of its own, Hong Kong Pharma conducts its operations through its wholly owned subsidiaries, Joint Cross Border Logistics Company Limited and V-Alliance Technology Supplies Limited, each a limited liability corporation incorporated in Hong Kong and collectively referred to as HK Subsidiaries. Our business offering consists of two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, primarily conducted through our Hong Kong subsidiary, Joint Cross Border, which we refer to as the “Supply Chain Services” division and (ii) OTC pharmaceutical cross-border procurement and distribution, primarily conducted through our Hong Kong subsidiary, V-Alliance, which we refer to as the “Procurement and Distribution” division.